Search clinical trials for: Fruquintinib plus camrelizumab and capecitabine

Total 5670 results

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

Unresectable/Metastatic Colorectal Cancer

China
Fudan University

Not yet recruiting

Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer

Colorectal Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Colorectal Neoplasm

China
Fudan University

Not yet recruiting

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

Colorectal Cancer | Colorectal Cancer Stage IV
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Beijing Friendship Hospital

Recruiting

A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy

Unresectable Metastatic Colorectal Cancer

China
Shandong Provincial Hospital

Unknown

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (MWA in NSCLC)

NSCLC Stage IV

China
Huazhong University of Science and Technology

Active, not recruiting

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

China
Huashan Hospital
Jiangsu HengRui Medicine Co., Ltd.; Shanghai Sunstem Biotechnology Co., Ltd.

Recruiting

Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Fudan University

Recruiting

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (BCTOP-T-N01)

TNBC - Triple-Negative Breast Cancer

China
Sun Yat-sen University

Recruiting

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Metastatic Colorectal Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

Colorectal Cancer

China
Sun Yat-sen University

Not yet recruiting

Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score

Locally Advanced Rectal Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Not yet recruiting

Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer

Colorectal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Terminated

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Sun Yat-sen University
Chengdu Biostar Pharmaceuticals

Not yet recruiting

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms | Locally Advanced or Metastatic Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer

Locally Advanced Gastric Cancer

China
Wuhan Union Hospital, China
Renmin Hospital of Wuhan University

Recruiting

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

Locally Advanced Rectal Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant Therapy | Resectable Lung Non-Small Cell Carcinoma | IMMUNOTHERAPY | Biomarkers / Blood

China
Zhang Bi Xiang, MD

Recruiting

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma (CCGLC-003)

Hyperbaric Oxygen Therapy | Combinational Immunotherapy | Hepatocellular Carcinoma Non-Resectable

China
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)

Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)

China
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Advanced Cervical Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Colorectal Neoplasms Malignant

China
Ruijin Hospital

Recruiting

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)

Head and Neck Cancer | Esophageal Squamous Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Unresectable Gallbladder Cancer

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
Lei Li

Recruiting

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Cervical Carcinoma | Immunotherapy | Survival Outcomes | Adverse Events | Locally Advanced Cervical Cancer | Chemoradiotherapy | Immune Checkpoint Inhibitor | Anti-programmed Cell Death Receptor 1 | Early Stage Cervical Cancer

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Metastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

Breast Neoplasms

China
Sun Yat-sen University

Recruiting

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Nasopharyngeal Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis)

Breast Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial (MAGIC)

Multiple Primary Lung Cancer

China
Fudan University

Not yet recruiting

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Triple-negative Breast Cancer

China
Second Affiliated Hospital of Nanchang University

Not yet recruiting

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Gastric Cancer
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
University of Southern California
National Cancer Institute (NCI)

Recruiting

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER)

Cancer | Metastatic | Breast | Triple Negative | Disseminated Tumor Cell

United States
Fudan University

Unknown

PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer

Metastatic Gastric Cancer | Locally Advanced Gastric Adenocarcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer

Unresectable Gallbladder Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

HER2 Positive Metastatic Breast Cancer

China
Sun Yat-sen University

Not yet recruiting

FOLFOX Chemotherapy Plus Fruquintinib and Sintilimab After First-line Treatment in Unresectable Hepatocellular Carcinoma (FOLFOX)

Hepatocellular Carcinoma | Immunotherapy | Second-line Treatment | Anti-angiogenic Therapy | FOLFOX Systemic Chemotherapy
Fudan University

Recruiting

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Triple-Negative Breast Cancer

China
Fudan University

Recruiting

Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

Locally Advanced Colon Cancer

China
Hutchison Medipharma Limited

Completed

Fruquintinib Food Effect and Proton Pump Inhibitor Study

Food-drug Interaction | Drug Interaction

United States
The First Affiliated Hospital of Henan University...

Recruiting

Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer

Esophageal Cancer

China

3

Subscribe